Physician profile
Edward C Wu
NPI 1265598718
$12,970.76
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,428 · 2020: $2,285 · 2021: $2,338 · 2022: $1,690 · 2023: $1,782 · 2024: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,424.28 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $2,328.22 | 2019-2022 | |
| Alkermes, INC. | $1,397.61 | 2019-2024 | Aristada, Lybalvi |
| Abbvie INC. | $1,394.13 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $987.89 | 2021-2024 | Caplyta |
| Allergan, INC. | $922.20 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $752.69 | 2019-2023 | Trintellix |
| Lundbeck LLC | $686.18 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $606.42 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $398.18 | 2019-2023 | Uzedy, Austedo |
| Eisai INC. | $350.43 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $321.66 | 2019-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $243.84 | 2024 | Auvelity |
| Indivior INC. | $98.58 | 2022-2023 | Perseris |
| Merck Sharp & Dohme LLC | $34.87 | 2021-2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.58 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.